Chronic Pain News and Research

RSS

BioDelivery Sciences International announces filing of Annual Report with U.S. SEC

BioDelivery Sciences International, Inc. has filed its Annual Report with the U.S. Securities and Exchange Commission on Form 10-K for the fiscal year ended December 31, 2009. Such Form 10-K is available on the SEC’s website at www.sec.gov.

20 Mar 2010

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Zogenix, Inc., a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain.

17 Mar 2010

StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

StockPreacher.com announces an investment report featuring ACADIA Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

17 Mar 2010

Pfizer-FRSQ-MSSS Chronic Disease Fund for chronic-disease prevention and management initiatives

The Fonds de la recherche en santé du Québec in partnership with the Ministère de la Santé et des Services sociaux and Pfizer Canada, is announcing the creation of the Pfizer-FRSQ-MSSS Chronic Disease Fund. Established with an investment of $5 million from Pfizer Canada, this research grant program, coordinated by the FRSQ, is open to Quebec-based researchers who work in collaboration with health professionals.

17 Mar 2010

Vertebroplasty: Patient selection vital

Patient selection is key for vertebroplasty—a minimally invasive treatment performed by interventional radiologists in individuals with painful osteoporotic vertebral compression fractures that fail to respond to conventional medical therapy—to be effective and successful, according to a study of more than 1,500 persons who were followed over seven years. Additionally, collaboration between an interventional radiologist and other medical experts in treating a patient is imperative, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

15 Mar 2010

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

Progenics Pharmaceuticals, Inc. today announced that it plans to advance oral methylnaltrexone for the treatment of opioid-induced constipation (OIC) into late stage clinical development and will commence a phase 2b/3 clinical trial of a methylnaltrexone tablet in chronic-pain patients in the second half of 2010. Progenics also announced data from a clinical trial of this methylnaltrexone tablet.

15 Mar 2010

New MMMCC center improves patients’ access to medical marijuana

Marijuana is not just for brownies anymore. It has touched the lives of thousands of Michigan residents who are struggling with chronic pain, severe nausea, seizures, spasms or wasting syndrome.

12 Mar 2010

Azur Pharma to acquire PRIALT analgesic therapy from Elan Pharmaceuticals

Azur Pharma Limited today announced it has signed a definitive agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion).

12 Mar 2010

National Public Health Agenda for Osteoarthritis launched with assistance from UNC

Betty Isaacs of Boone, N.C., knows all about the chronic pain of osteoarthritis and the impact it has on her life. "The pain in my knee was so bad, I would just sit around," Isaacs said.

11 Mar 2010

XenaCare Holdings' Cobroxin to be available for purchase in Walgreens

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be available for purchase in Walgreens by May 1, 2010. Walgreens is considered one of the nation’s largest pharmacy chains with 7,162 drugstores located throughout the United States.

11 Mar 2010

AAOS 2010 meeting highlights emerging incidence of pediatric sports injuries

At today's 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), two separate studies focus on the dramatic rise of pediatric sports injuries in recent years. However, despite this alarming trend, awareness, education, warning signs and early treatment can make a significant difference and help keep these athletes in the game, according to the study experts.

11 Mar 2010

Childhood bad behaviour linked to chronic widespread pain in adult life

Bad behaviour in childhood is associated with long-term, chronic widespread pain in adult life, according to the findings of a study following nearly 20,000 people from birth in 1958 to the present day.

10 Mar 2010

International Merchant Advisors creates IMAI Wellness Centers in Colorado

International Merchant Advisors, Inc. www.imaiinc.com announced today that the company has created a new subsidiary in Colorado, IMAI Wellness Centers, Inc., to pursue the development of the company's new Wellness Centers and Medical Marijuana clinics for chronic pain relief.

9 Mar 2010

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

Bristol-Myers Squibb Company and Allergan, Inc. today announced a global agreement for the development and commercialization of AGN-209323, a Phase II-ready, orally administered small molecule in clinical development for neuropathic pain.

3 Mar 2010

FDA approves CombinatoRx's NDA for Exalgo extended-release tablets

CombinatoRx, Incorporated today announced that the U.S. Food and Drug Administration has approved the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

2 Mar 2010

IMAI reaches agreement in principal to acquire Organic Science for $15M

International Merchant Advisors, Inc. www.imaiinc.com announced today that the company has reached an agreement in principal to acquire its first operating business in the clinical medical marijuana space. IMAI has agreed to acquire Organic Science, Inc. for $15 million in the restricted common stock of IMAI.

2 Mar 2010

TMI's Glider balloon catheter for PTA of lesions in peripheral vasculature receives FDA marketing clearance

TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for its newest product, the Glider™ balloon catheter, for percutaneous transluminal angioplasty (PTA) of lesions in the peripheral vasculature including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries.

25 Feb 2010

Study: People can reduce their sensitivity to pain by thickening their brain

People can reduce their sensitivity to pain by thickening their brain, according to a new study published in a special issue of the American Psychological Association journal, Emotion. Researchers from the Universit- de Montr-al made their discovery by comparing the grey matter thickness of Zen meditators and non-meditators.

25 Feb 2010

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

MicroTransponder, Inc., a privately-held medical device company, has just announced a $7 Million Series B round of funding. MicroTransponder is developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications.

25 Feb 2010

Aetna selects Millennium Laboratories as national pain management services provider

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, announced today a national agreement with Aetna, one of the nation’s leading diversified health care benefits companies that serves approximately 36.3 million people. Under the terms of the three-year ancillary services agreement which went into effect February 1, 2010, Millennium Laboratories’ will assist Aetna participating physicians nationwide with state-of-the-art therapeutic drug monitoring services and tools.

23 Feb 2010

Chronic Pain News and Research

BioDelivery Sciences International announces filing of Annual Report with U.S. SEC

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

Pfizer-FRSQ-MSSS Chronic Disease Fund for chronic-disease prevention and management initiatives

Vertebroplasty: Patient selection vital

Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development

New MMMCC center improves patients’ access to medical marijuana

Azur Pharma to acquire PRIALT analgesic therapy from Elan Pharmaceuticals

National Public Health Agenda for Osteoarthritis launched with assistance from UNC

XenaCare Holdings' Cobroxin to be available for purchase in Walgreens

AAOS 2010 meeting highlights emerging incidence of pediatric sports injuries

Childhood bad behaviour linked to chronic widespread pain in adult life

International Merchant Advisors creates IMAI Wellness Centers in Colorado

AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement

FDA approves CombinatoRx's NDA for Exalgo extended-release tablets

IMAI reaches agreement in principal to acquire Organic Science for $15M

TMI's Glider balloon catheter for PTA of lesions in peripheral vasculature receives FDA marketing clearance

Study: People can reduce their sensitivity to pain by thickening their brain

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

Aetna selects Millennium Laboratories as national pain management services provider

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News